Drug Trial Radar · NCT00870740
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Aug 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
517
Actual
Start
Feb 2009
Primary completion
May 2012
Study completion Oct 2012
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Mar 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to assess the safety and immunogenicity of extended treatment with DAC HYP. This evaluation included the following major components: * An assessment of safety and immunogenicity of extended treatment with DAC HYP when administered to MS subjects who had completed 52 weeks of active therapy with DAC HYP in Study 201. * An assessment of safety and immunogenicity during a 6-month washout period from DAC HYP. * An assessment of safety and immunogenicity during reinitiation of therapy with DAC HYP after a 6-month washout period. * An assessment of safety and immunogenicity of DAC HYP when administered to MS subjects who previously received placebo during Study 201. The secondary objective is to assess the durability of the effect of DAC HYP on multiple sclerosis (MS) disease activity as measured by brain magnetic resonance imaging (MRI) scans and clinical MS relapses.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process)Biological
SC injection
PlaceboDrug
Placebo SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (AEs)Time frame: Up to 72 weeks
- Number of Participants With Abnormalities in Vital SignsTime frame: Up to Week 72
- Number of Participants With Potentially Clinically Significant Hematology Laboratory AbnormalitiesTime frame: Up to 72 Weeks
- Number of Participants With Abnormalities in Blood Chemistry Laboratory DataTime frame: Up to 72 Weeks
- Number of Participants With Development of Anti-DAC Antibodies (ADAb) and Neutralizing Antibodies (NAb) Post-baselineTime frame: Up to 72 weeks
Locations
58 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Brno, Czechia
Research Site
Hraddec Kralove, Czechia
Research Site
Olomouc, Czechia
Research Site
Pilsen, Czechia
Research Site
Prague, Czechia
Research Site
Teplice, Czechia
Research Site
Bayreuth, Germany
Research Site
Erlangen, Germany
Research Site
Marburg, Germany
Research Site
Osnabrück, Germany
Research Site
Regensburg, Germany
Research Site
Rostock, Germany
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Esztergom, Hungary
Research Site
Győr, Hungary
Research Site
Kecskemét, Hungary
Research Site
Miskolc, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Siófok, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Andra-Pradeash, India
Research Site
Bangalore, India
Research Site
Jaipur, India
Research Site
Kolkata, India
Research Site
Mumbai, India
Research Site
Visakhapatnam, India
Research Site
Bialystok, Poland
Research Site
Gdansk, Poland
Research Site
Katowice, Poland
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Warsaw, Poland
Research Site
Kazan', Russia
Research Site
Krasnoyarsk, Russia
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Research Site
Novosibirsk, Russia
Research Site
Omsk, Russia
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.